Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
The STOP-CA trial showed that statins can help chemotherapy patients avoid potential side effects related to anthracycline agents. Co-principal investigators Marielle Scherrer-Crosbie, MD, and Tomas Neilan, MD, discussed the details of that trial at ACC.23.
Eric Secemsky, MD, told Cardiovascular Business that a lack of training is one of the biggest factors limiting the use of intravascular imaging-guided PCI among interventional cardiologists.
The study’s primary endpoint, amputation-free survival after six months, was seen in 66.1% of CLTI patients who underwent transcatheter arterialization.
Weekend warriors who take brisk walks of around four miles just once or twice per week enjoy lower cardiovascular and all-cause mortality than their sedentary peers.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
